193 related articles for article (PubMed ID: 23646393)
1. [ASCO 2006: temsirolimus increases survival].
Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
[No Abstract] [Full Text] [Related]
2. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
[TBL] [Abstract][Full Text] [Related]
3. Temsirolimus for advanced renal-cell carcinoma.
Ferretti G
N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17823993
[No Abstract] [Full Text] [Related]
4. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
5. Temsirolimus in renal cell carcinoma.
Otto T; Eimer C; Gerullis H
Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
[TBL] [Abstract][Full Text] [Related]
6. Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma.
Alemao E; Rajagopalan S; Yang S; Curiel RE; Purvis J; Al MJ
J Med Econ; 2011; 14(2):245-52. PubMed ID: 21417551
[TBL] [Abstract][Full Text] [Related]
7. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
8. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.
Kwitkowski VE; Prowell TM; Ibrahim A; Farrell AT; Justice R; Mitchell SS; Sridhara R; Pazdur R
Oncologist; 2010; 15(4):428-35. PubMed ID: 20332142
[TBL] [Abstract][Full Text] [Related]
9. How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma.
Escudier B
J Clin Oncol; 2010 May; 28(13):2125-6. PubMed ID: 20368540
[No Abstract] [Full Text] [Related]
10. In focus: bevacizumab for renal cell carcinoma.
Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
[No Abstract] [Full Text] [Related]
11. Active tuberculosis during temsirolimus and bevacizumab treatment.
Lin CC; Wang JY; Pu YS
J Clin Oncol; 2013 Jan; 31(2):e18-20. PubMed ID: 23169507
[No Abstract] [Full Text] [Related]
12. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
13. [Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?].
Doehn C; Merseburger AS; Jocham D; Kuczyk MA
Urologe A; 2007 Oct; 46(10):1371-2, 1374, 1376-8. PubMed ID: 17805507
[TBL] [Abstract][Full Text] [Related]
14. Temsirolimus: new drug. Metastatic kidney cancer: more assessment needed.
Prescrire Int; 2008 Dec; 17(98):223-5. PubMed ID: 19415885
[TBL] [Abstract][Full Text] [Related]
15. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
Figlin RA; de Souza P; McDermott D; Dutcher JP; Berkenblit A; Thiele A; Krygowski M; Strahs A; Feingold J; Boni J; Hudes G
Cancer; 2009 Aug; 115(16):3651-60. PubMed ID: 19526589
[TBL] [Abstract][Full Text] [Related]
16. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus.
Lee CK; Marschner IC; Simes RJ; Voysey M; Egleston B; Hudes G; de Souza P
Clin Cancer Res; 2012 Jun; 18(11):3188-96. PubMed ID: 22472176
[TBL] [Abstract][Full Text] [Related]
17. [Systemic therapy for metastatic renal cell carcinoma].
Kramer MW; Steffens S; von Klot C; Merseburger AS; Kuczyk MA
Aktuelle Urol; 2012 Jul; 43(4):265-8. PubMed ID: 22869498
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
[TBL] [Abstract][Full Text] [Related]
19. Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma.
Korhonen P; Zuber E; Branson M; Hollaender N; Yateman N; Katiskalahti T; Lebwohl D; Haas T
J Biopharm Stat; 2012; 22(6):1258-71. PubMed ID: 23075021
[TBL] [Abstract][Full Text] [Related]
20. [Drug now immediately available in Germany].
Aktuelle Urol; 2006 Sep; 37(5 Suppl):18-9. PubMed ID: 23646396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
